Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.17
+0.05000.62%
Post-market: 8.15-0.0200-0.24%19:30 EDT
Volume:6.15M
Turnover:49.61M
Market Cap:2.09B
PE:-5.43
High:8.20
Open:8.12
Low:7.92
Close:8.12
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.93
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-4.60
PE(LYR):6.75

Loading ...

Emergent BioSolutions Swings to Q2 Loss on Impairment Charge; to Cut Jobs

Reuters
·
Aug 06

Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 05

BioCryst Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales

Reuters
·
Aug 05

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15

MT Newswires Live
·
Aug 05

BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M Estimate

Benzinga Earnings
·
Aug 05

BioCryst Pharmaceuticals Outlook FY Sales USD 690-715 Million

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals Q2 EPS USD 0.3

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash and Investments $354 Mln at June 30, 2026

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals - Expects Additional Costs for Discovery Center Closure; Analysis Ongoing - SEC Filing

THOMSON REUTERS
·
Aug 04

BioCryst Pharmaceuticals - Estimates $6.2-$7.50 Mln in One-Time Expenses for Termination Benefits, $5.3-$6.60 Mln Cash - SEC Filing

THOMSON REUTERS
·
Aug 04

BioCryst Amends 8-K, Estimates $6.2 Million-$7.5 Million in One-Time Severance Costs for Discovery Shutdown Plan

Reuters
·
Aug 04

BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?

Simply Wall St.
·
Aug 04

Earning Preview: Biocryst Pharmaceuticals Q2 revenue is expected to increase by 21.89%, and institutional views are cautiously optimistic

Earnings Agent
·
Jul 29

Biocryst to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Jul 22

Biocryst Names David Jenkins Chief Scientific Officer

Reuters
·
Jul 15

Biocryst Appoints David W. Jenkins as Chief Scientific Officer

THOMSON REUTERS
·
Jul 15

BioCryst (BCRX) Receives a Buy from Wedbush

TIPRANKS
·
Jul 13

Biocryst Pharmaceuticals Price Target Announced at $12.00/share by JP Morgan

Dow Jones
·
Jul 13